Michael. W. Fried
#149,670
Most Influential Person Now
Michael. W. Fried's AcademicInfluence.com Rankings
Michael. W. Friedphilosophy Degrees
Philosophy
#8225
World Rank
#11564
Historical Rank
Logic
#5258
World Rank
#6643
Historical Rank

Download Badge
Philosophy
Why Is Michael. W. Fried Influential?
(Suggest an Edit or Addition)Michael. W. Fried's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. (2002) (6617)
- EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2011) (1454)
- Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005) (1285)
- Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. (2014) (1153)
- A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. (2000) (959)
- Response-guided telaprevir combination treatment for hepatitis C virus infection. (2011) (799)
- EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2014) (783)
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. (2015) (761)
- Side effects of therapy of hepatitis C and their management (2002) (744)
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. (2015) (694)
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. (2005) (569)
- Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. (1995) (566)
- Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. (2006) (495)
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. (2017) (484)
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (2014) (469)
- Liver transplantation for acute liver failure from drug induced liver injury in the United States (2004) (439)
- Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. (1994) (381)
- Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C (2001) (343)
- A pilot study of ribavirin therapy for chronic hepatitis C (1992) (300)
- Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study (2013) (295)
- Side effects of therapy of hepatitis C and their management (2002) (293)
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response (2007) (289)
- Side effects of therapy for chronic hepatitis C. (2003) (273)
- Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function (2016) (267)
- Ribavirin as Therapy for Chronic Hepatitis C (1995) (263)
- Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. (2014) (252)
- HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B (2008) (247)
- Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. (2007) (216)
- Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. (2011) (206)
- Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. (2016) (206)
- Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. (2010) (188)
- Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial (2005) (179)
- Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. (2016) (178)
- Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. (1995) (175)
- Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment (2017) (174)
- Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract (2008) (173)
- Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. (2001) (167)
- Ribavirin potentiates interferon action by augmenting interferon‐stimulated gene induction in hepatitis C virus cell culture models (2011) (162)
- Barriers to hepatitis C treatment (2012) (161)
- Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. (2012) (142)
- Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C (2010) (137)
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study (2014) (135)
- Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study (2017) (134)
- Hepatitis C virus treatment in the real world: optimising treatment and access to therapies (2015) (133)
- Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). (2002) (133)
- Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B (2002) (131)
- Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response (2011) (124)
- Current therapy for hepatitis C: pegylated interferon and ribavirin. (2003) (122)
- Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study (2001) (117)
- Increasing Hepatitis C Virus RNA Levels in Hemophiliacs: Relationship to Human Immunodeficiency Virus Infection and Liver Disease (1994) (117)
- Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure (2018) (116)
- Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. (2007) (110)
- Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network (2015) (110)
- A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care (2013) (109)
- Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States (2004) (107)
- Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. (2005) (107)
- R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin (2008) (103)
- Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. (2001) (101)
- Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? (1998) (100)
- Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. (2015) (98)
- Social Stigmatization and Hepatitis C Virus Infection (2006) (92)
- The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity (2008) (91)
- Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA (1995) (87)
- Sequence Heterogeneity of TT Virus and Closely Related Viruses (2000) (84)
- Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States (2020) (82)
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
- Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. (1995) (80)
- Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin (2008) (80)
- Severe villus atrophy and chronic malabsorption induced by azathioprine. (2003) (79)
- Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin (2002) (77)
- Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. (1992) (77)
- Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial (2004) (76)
- Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. (2004) (75)
- Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study (2016) (75)
- Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. (2015) (75)
- Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C: Results of the Virahep-C Study (2009) (74)
- A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. (1993) (71)
- American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. (2017) (70)
- Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin (2008) (70)
- Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C (2005) (66)
- A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment (2011) (65)
- Assessing the Validity of Self-Reported Medication Adherence in Hepatitis C Treatment (2007) (64)
- Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome (2001) (63)
- PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL (2013) (59)
- Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin (2007) (58)
- High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use Comorbidities (2007) (58)
- Management of hepatitis C in the hemophilia patient. (1999) (57)
- Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. (2012) (57)
- A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype (2000) (56)
- Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection (2006) (54)
- Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C (2011) (54)
- Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. (2003) (53)
- Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential (2014) (52)
- Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C (2013) (52)
- All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database (2017) (50)
- Prospective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests (2001) (49)
- LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target (2015) (48)
- Barriers to accessing care in patients with chronic hepatitis C: the impact of depression (2010) (48)
- Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial (2019) (48)
- Hepatitis B and C and renal failure. (2001) (48)
- Natural history and disease manifestations of hepatitis C infection. (2000) (47)
- Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B‐induced end stage liver disease (2006) (47)
- Determination of hepatitis B phenotype using biochemical and serological markers (2017) (46)
- Therapy of chronic hepatitis B with a 6-month course of ribavirin. (1994) (42)
- Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. (2016) (41)
- Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis (1993) (40)
- O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience (2015) (38)
- A pilot study of 2′,3′‐dideoxyinosine for the treatment of chronic hepatitis B (1992) (35)
- Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
- Chronic hepatitis B: a critical appraisal of current approaches to therapy. (2006) (34)
- Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues (2012) (33)
- 2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL (2012) (32)
- Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial (2013) (32)
- Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials (2014) (32)
- Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study. (2019) (31)
- High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study (2016) (30)
- Viral factors affecting the outcome of therapy for chronic hepatitis C. (2004) (30)
- 993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN (2008) (30)
- 1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT (2011) (29)
- Thursday, 24 AprilParallel Session 1: HEPATITIS C THERAPY7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2008) (29)
- Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir (2015) (29)
- 50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B (2006) (29)
- Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection (2014) (29)
- Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. (2012) (28)
- Creatine kinase isoenzymes in the diagnosis of intestinal infarction (1991) (28)
- Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? (2013) (27)
- Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy. (2019) (26)
- Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence (2013) (26)
- Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. (2011) (26)
- High relapse rate seen at week 72 for patients treated with R1626 combination therapy (2008) (24)
- Advances in therapy for chronic hepatitis C. (2001) (24)
- Orthotopic liver transplantation for biliary papillomatosis (2001) (24)
- Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. (2019) (24)
- Intensive Interferon Therapy Does Not Increase Virological Response Rates in African Americans with Chronic Hepatitis C (2004) (23)
- MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure (2017) (23)
- Internal biliary stenting in orthotopic liver transplantation (2000) (22)
- A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study (2018) (22)
- 881 HIGH SVR RATES (SVR4) FOR 12-WEEK TOTAL TELAPREVIR COMBINATION THERAPY IN IL28B CC TREATMENT-NAÏVES AND PRIOR RELAPSERS WITH G1 CHRONIC HEPATITIS C: CONCISE INTERIM ANALYSIS (2013) (21)
- Hepatitis C virus: a critical appraisal of approaches to therapy. (2009) (21)
- Unexpected Maintenance of Hepatitis C Viral Diversity following Liver Transplantation (2012) (21)
- Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies (2015) (20)
- 1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN (2010) (20)
- 1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2011) (19)
- Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: A matched, case‐controlled study (2002) (19)
- Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis (2018) (18)
- Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection (2018) (18)
- Psychiatric symptoms during interferon treatment for hepatitis C:experiences from a tertiary care hepatology centre (2008) (18)
- Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C (2012) (18)
- Factors Associated with Readmission in the US Following Hospitalization with COVID-19 (2021) (17)
- Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance. (2006) (17)
- Diagnostic testing for hepatitis C: practical considerations. (1999) (17)
- MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure (2017) (17)
- TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY (2011) (17)
- Elevated AST‐to‐platelet ratio index is associated with increased all‐cause mortality among HIV‐infected adults in Zambia (2015) (17)
- A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection (2019) (17)
- Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation (2020) (16)
- Optimizing treatment regimens in hepatitis C. (2006) (16)
- Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy (2020) (16)
- Plasma levels of growth‐related oncogene (CXCL1‐3) associated with fibrosis and platelet counts in HCV‐infected patients (2015) (16)
- Guidelines for stopping therapy in chronic hepatitis C (2004) (16)
- 1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2012) (15)
- Hepatitis C and alcohol: fundamental and translational research directions. (2003) (15)
- Persistent Portosystemic Shunts After Liver Transplantation Causing Episodic Hepatic Encephalopathy (2010) (15)
- An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots (2018) (15)
- Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients (2013) (15)
- Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. (2017) (14)
- Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia (2015) (14)
- 11 IMPACT OF IL28B GENOTYPE AND PRETREATMENT SERUM IP-10 IN TREATMENT-NAIVE GENOTYPE-1 HCV PATIENTS TREATED WITH TMC435 IN COMBINATION WITH PEGINTERFERONa-2A AND RIBAVIRIN IN PILLAR STUDY (2011) (14)
- The role of triple therapy in HCV genotype 1‐experienced patients (2011) (14)
- Modified piggyback technique for adult orthotopic liver transplantation. (2000) (13)
- Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort (2018) (13)
- Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. (2017) (13)
- Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C (2012) (13)
- A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy (1999) (13)
- Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. (2017) (12)
- Prevalence and factors associated with statin use among patients with non-alcoholic fatty liver disease in TARGET-NASH. (2021) (12)
- Nitazoxanide: beyond parasites toward a novel agent for hepatitis C. (2009) (12)
- 943f TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of The ASPIRE Trial (2012) (11)
- What’s Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment (2017) (11)
- Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals (2019) (11)
- 1168 IL28B GENETIC VARIATION ASSOCIATED WITH EARLY VIRAL KINETICS AND SVR IN HCV GENOTYPE 1 THE VIRAHEP-C STUDY (2010) (10)
- Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B (2017) (10)
- 49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB) (2006) (9)
- Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity (2015) (9)
- 522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR) (2004) (9)
- A multicenter, randomized trial of daily, high dose interferon-alpha 2b for the treatment of chronic hepatitis C: Prospective stratification by viral burden and genotype (1998) (9)
- Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis (2019) (9)
- A real‐world observational cohort of patients with primary biliary cholangitis: TARGET‐primary biliary cholangitis study design and rationale (2018) (9)
- Hepatitis C infection with normal liver chemistry tests. (2008) (8)
- P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study (2015) (8)
- Hepatitis C viral infection in patients with hemophilia and hemolytic disorders (2012) (8)
- Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-NaïVE Patients Regardless of Race or Ethnicity (2011) (8)
- Patient‐reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross‐sectional analysis (2020) (8)
- 761 Expanding the donor pool by transplanting cadaveric livers from older donors: an analysis of patient and graft survival by donor age from the United Network for organ sharing database (2003) (7)
- Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Interim Analysis (2016) (7)
- Treatment options of patients with chronic hepatitis C who have failed prior therapy (2016) (7)
- Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy (2012) (6)
- Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem (2016) (6)
- Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. (2019) (6)
- Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis (2021) (6)
- The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. (2018) (6)
- Idiopathic CD4+ T‐lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men (1995) (6)
- Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: Results from the PROP UP study (2021) (6)
- 995 A dynamic model to predict sustained virological response to combination peginterferon alfa-2A (40KD) (PEGASYS(®)) and ribavirin (COPEGUS(®)) therapy in patients with chronic hepatitis C (2003) (5)
- 764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study (2014) (5)
- Controversies in hepatitis C therapy: Reactivation of hepatitis B virus (2017) (5)
- “If I Get Cured, My Whole Quality of Life Will Change”: Patients’ Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C (2021) (5)
- Case studies of the hepatitis B patient: a panel discussion. (2000) (5)
- P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis (2015) (5)
- Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study (2017) (4)
- Safety and Efficacy of New Daa Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Interval Results from the HCV-Target Study (2016) (4)
- 956 – Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hcv Genotype 1-6: Results of the Hcv-Target Study (2019) (4)
- P1127 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS (2014) (4)
- Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS) compared with standard inferferon alfa-2a (2001) (4)
- Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (PEGASYSTM) and thrice weekly interferon alfa-2a (RoferonTM) in patients with chronic hepatitis C without cirrhosis (2000) (4)
- Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C (2018) (4)
- Chronic hepatitis B virus monoinfection at a university hospital in Zambia (2018) (4)
- HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape (2015) (4)
- Hepatitis C: Current options for nonresponders to peginterferon and ribavirin (2008) (4)
- Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV (2021) (4)
- Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentretreatment Protocol (2016) (3)
- Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study (2021) (3)
- High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV‐infected patients regardless of DPP4 activity (2016) (3)
- A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (2021) (3)
- Clinical Practice Guidelines : Management of hepatitis C virus infection European Association for the Study of the Liver ⇑ (2013) (3)
- Real‐world evidence in hepatocellular carcinoma (2021) (3)
- A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy (2018) (3)
- Incidence of and predictors for direct acting antiviral treatment failure among 3909 hepatitis C genotype 1 infected adults: real world outcomes from HCV TARGET (2017) (3)
- 17 Hepatitis C and renal disease (2000) (3)
- Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial (2019) (3)
- 1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis (2015) (3)
- Twice Daily Dosing of Telaprevir for Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Infection (2014) (3)
- THU-181-Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study (2019) (3)
- 8 Patient and graft survival after adult living donor liver transplantation compared to cadaveric liver transplantation in patients with chronic hepatitis C: an analysis of the United network for organ sharing database (2003) (3)
- Sequence heterogeneity within three different regions of the hepatitis G virus genome. (1999) (2)
- The FDA, bridging data, and hepatitis C (2013) (2)
- Management of newly diagnosed hepatitis C virus infection. (2003) (2)
- Quantitation of Pretreatment Serum IP-10 Improves the Predictive Value of an IL28B Gene Polymorphism for Hepatitis C Treatment Response (2011) (2)
- Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy (2020) (2)
- Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination with Sofosbuvir in Naive Subjects with HCV Genotype 1 Short Title: Telaprevir & Sofosbuvir in HCV Genotype 1 (2015) (2)
- 1117 Increasing liver-related mortality in incarcerated populations (2003) (2)
- Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C (2017) (2)
- Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". (2019) (2)
- Treatment Effect and Resistance Profiles were Similar Between Black/African American and Non-Black/African American Patients Treated with a Telaprevir Combination Regimen (2011) (2)
- O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY (2014) (2)
- Safety and efficacy of elbasvir and grazoprevir with or without ribavirin for the treatment of hepatitis C virus genotype 1: results of the hepatitis C virus-TARGET study (2017) (1)
- HCV: The Journey from Discovery to a Cure: Volume II (2019) (1)
- PANTOPRAZOLE REDUCES THE SIZE OF POST-BANDING ULCERS AFTER ELECTIVE ENDOSCOPIC VARICEAL BAND LIGATION: A RANDOMIZED, CONTROLLED TRIAL (2004) (1)
- 550 Hemophilic siblings with chronic hepatitis C: evidence of a genetic association with disease progression (2003) (1)
- O116 HEPATITIS B SURFACE ANTIGEN (HBsAg) LEVELS DIFFER ACROSS HBV GENOTYPE AND PHENOTYPE: RESULTS FROM THE ADULT COHORT STUDY OF THE NIDDK-SPONSORED HEPATITIS B RESEARCH NETWORK (2014) (1)
- 388 Race, insulin resistance, visceral adiposity and hepatic steatosis in genotype 1 patients with chronic hepatitis C (2003) (1)
- Su1428 Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicenter Treatment Protocol (2016) (1)
- Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation (2023) (1)
- Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study (2016) (1)
- HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. (2019) (1)
- 410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS (2011) (1)
- Poster Session I (PI 1–89) (2009) (1)
- Speech patterns and enunciation for encephalopathy determination—A prospective study of hepatic encephalopathy (2022) (1)
- THU-182-The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C-transforming decision-making for patients, providers, and stakeholders (2019) (1)
- Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
- Changes in Health for Patients Who Complete Treatment for Chronic Hepatitis C Virus -- The PROP up TARGET Study (2020) (1)
- Parsing the guidelines on guidelines: Balancing sensibility and conflict of interest (2018) (1)
- Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir. (2021) (1)
- [658] OPTIMAL PRE-TREATMENT HCV-RNA LEVEL FOR PREDICTION OF SVR WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN IN GENOTYPE 1 PATIENTS: GENERALISED ADDITIVE LOGISTIC REGRESSION MODEL (GAM) ANALYSIS (2007) (0)
- Sa1463 - Associations of Alcohol Consumption Motives with Depression and Pain Among Individuals with Hepatitis C (2018) (0)
- 1013 High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/R, Dasabuvir With or Without Ribavirin for 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials (2015) (0)
- O121: Peg‐IFN/RBV plus second‐generation protease inhibitors (2013) (0)
- 25. Hepatitis C (2011) (0)
- Erratum: Decreasing fibrogenesis. An immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B (Journal of Hepatology (2001) 35 (749-755) PII:S0168827801002185) (2002) (0)
- Treatment of chronic hepatits C virus (HCV) infection with a modified form of Interferon alfa-2a (IFN) containing a branched, 40 kDa polyethylene glycol (PEG) moiety: virological results in patients with and without cirrhosis (1999) (0)
- Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC (2018) (0)
- CHOLEDOCHOCHOLEDOCHOSTOMY IN LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS (1999) (0)
- Reply to authors. (2018) (0)
- Comparing Oral Medicines to Treat Hepatitis C Virus -- The PRIORITIZE Study (2022) (0)
- Response by Dr. Oates et al. [1] (1992) (0)
- Primary Care Providers in Federally Qualified Health Centers Can Treat Hepatitis C Effectively Without Ongoing Consultative Support From Specialists (2021) (0)
- OUTCOMES COMPARISON OF PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATITIS B AND HEPATITIS C (1998) (0)
- Metastatic leiomyosarcoma mimicking polycystic liver disease (2002) (0)
- Mo1451 - Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in Target-PBC (2018) (0)
- HCV Genotype 1: How are you Managing the Non-Responders and Relapsers? A North American Perspective (2010) (0)
- PREVALENCE OF LOW BONE MASS AND RISK FACTORS IN PATIENTS AWAITING LIVER TRANSPLANTATION.: Abstract# 783 Poster Board #‐Session: P40‐III (2000) (0)
- There are no formulae for determining how large a sample is needed in multiple regression or any multivariate technique. (1992) (0)
- 492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB) (2006) (0)
- Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort. (2023) (0)
- 322 Baseline psychosocial characteristics of participants in the virahep-C study (2003) (0)
- Real-World Evidence and Hepatitis C (2019) (0)
- Killing Two Birds With No Stone (2021) (0)
- Reply: (2009) (0)
- Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) (2003) (0)
- Letters to the editor (2005) (0)
- Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. (2023) (0)
- Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV-TARGET Cohort (2018) (0)
- P767 PLASMA LEVELS OF GRO ASSOCIATE WITH FIBROSIS AND PLATELET COUNTS IN HCV INFECTED PATIENTS FROM THE VIRAHEP-C COHORT (2014) (0)
- Prevalence and impact of hepatitis E virus infection in the Hepatitis B Research Network cohort (2018) (0)
- Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial. (2023) (0)
- Safety of Paritaprevir/Ritonavir/Ombitasvir + Dasabuvir with or without rivavirin in HCV Genotype 1-infected Patients : Results from Phase 2 a,d 3 Trails (2015) (0)
- Interferon alfa-2b and ribavirin combinations is effective in patients with hemophilia and chronic hepatitis C (2003) (0)
- Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1 (2015) (0)
- Intensive daily high dose interferon does not overcome antiviral reslstance in African Americans with chronic hepatitis C (2001) (0)
- Treatment With Silymarin for Hepatitis C Virus—Reply (2012) (0)
- Viral Hepatitis: Acute and Chronic Disease (2009) (0)
- CRITICAL EVALUATION OF LIVING DONORS FOR LIVING DONOR LIVER TRANSPLANTATION.: Abstract# 232 Poster Board #‐Session: P79‐I (2000) (0)
- P1189 HIGH MIG (CXCL9) PLASMA LEVEL FAVORS RESPONSE TO PEGINTERFERON AND RIBAVIRIN IN HCV INFECTED PATIENTS BUT IS NOT LINKED TO DPP4 ACTIVITY (2014) (0)
- Editorial: targeting liver biopsy in NAFLD—the need to expand our non‐invasive tools. Authors’ reply (2021) (0)
- Internal Biliary Stenting in Orthotopic Liver Transplantation using a 6 Fr. Silastic™ Double J Ureteral Stent (1999) (0)
- Primary biliary cholangitis (PBC) in the U.S.: clinical characteristics of patients enrolled in TARGET-PBC (2018) (0)
- 1166 THE PREDICTIVE VALUE OF IL28B GENE POLYMORPHISM FOR RESPONSE TO PEGINTERFERON AND RIBAVIRIN IS ENHANCED BY QUANTITATION OF IP-10 IN PRETREATMENT SERUM (2010) (0)
- Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection (2018) (0)
- Hepatitis C virus (HCV) genotypes 2 3 infection: A curable disease (2003) (0)
- W1011 Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Silymarin (SM) Following Chronic Dosing in Patients with Chronic Hepatitis C (HCV) (2008) (0)
- Response‐guided therapy for acute hepatitis C: applying concepts from chronic treatment (2011) (0)
- Mo1442 - Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in Target-PBC (2018) (0)
- Host liver gene regulation during chronic infection with the hepatitis C virus (2001) (0)
- Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?" (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael. W. Fried?
Michael. W. Fried is affiliated with the following schools: